Form 4: Lipocine Director Spyros Papapetropoulos Granted Stock Options

Lipocine Inc. Director and 10% Owner, Spyros Papapetropoulos, was granted 1,764 stock options with an exercise price of $3.20 per share.

Summary

• Spyros Papapetropoulos, a Director and 10% Owner of Lipocine Inc. (LPCN), was granted 1,764 stock options.
• The transaction date for the option grant was June 4, 2025.
• The options have an exercise price of $3.20 per share.
• These options will vest 100% one year from the date of grant, specifically on June 4, 2026.
• The expiration date for these stock options is June 4, 2035.
• Following this transaction, Spyros Papapetropoulos beneficially owns 7,174 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates continued alignment of a director's interests with the company's performance through equity compensation, which is a standard practice.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the options gain value if the stock price increases.
• The options have a long expiration date (June 4, 2035), providing a significant window for potential value realization.

Future Outlook

The granted stock options are set to vest 100% one year from the grant date, on June 4, 2026, indicating a future milestone for the reporting person's equity holdings.

Industry Context

This filing is a routine disclosure of an insider transaction, common across all publicly traded companies. It reflects a standard practice of compensating directors with equity to align their interests with long-term shareholder value.

Related Party Transactions

• The grant of stock options to Spyros Papapetropoulos, a Director and 10% Owner of Lipocine Inc., constitutes a related party transaction as it involves an equity award to an insider.

Stakeholder Impact

• Shareholders: The grant of options could lead to minor future dilution if exercised, but it also serves to align the director's financial interests with shareholder value creation.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The granted stock options will vest on June 4, 2026, at which point they become exercisable.

Key Dates

Keywords

Lipocine Inc., LPCN, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Beneficial Ownership